Zomedica Corp. (ZOMDF) awards 250,000 options to senior sales VP

Q: What are the key terms of the 250,000 options granted at Zomedica (ZOMDF)?

The award consists of 250,000 options to buy Zomedica Common Stock, with a conversion or exercise price of 0.0900 per share and an expiration date of August 4, 2036 , all held directly by Sr Vice President, Sales Russell Kevin Klass after the grant.

Q: How do the Zomedica (ZOMDF) options granted to Russell Kevin Klass vest?

According to the vesting schedule, one quarter (1/4) of the options vest on the first anniversary of the grant date, and the remaining three quarters vest in equal monthly installments (1/48 each month) until the grant is fully vested on August 4, 2030 .

Q: Is the Zomedica (ZOMDF) transaction a purchase or sale of shares?

The transaction is coded as a grant, award, or other acquisition of derivative securities, meaning options were awarded to Russell Kevin Klass. There is no reported sale or disposition of Zomedica Common Stock in this report, and his directly held options position became 250,000 .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Zomedica Corp. reported that Sr Vice President, Sales Russell Kevin Klass received a grant of 250,000 options to buy Common Stock on August 5, 2026, with a conversion or exercise price of 0.0900 per share and an expiration date of August 4, 2036.

The options vest 25% on the first anniversary of the grant date, then in equal monthly installments until fully vested on August 4, 2030. Following this award, he holds 250,000 options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Klass Russell Kevin

Role Sr Vice President, Sales

Type	Security	Shares	Price	Value
Grant/Award	Options to buy Common Stock ^F1	250,000	$0.00	$0.00

Holdings After Transaction: Options to buy Common Stock — 250,000 shares (Direct)

Footnotes (1)

F1. one quarter (1/4) of the options to vest on the first anniversary of the date of grant and 1/48 to vest monthly thereafter until fully vested on 8/4/2030

Key Figures

Options granted: 250000.0000 options Exercise price: 0.0900 per share Expiration date: 2036-08-04 +2 more

5 metrics

Options granted 250000.0000 options Grant of options to buy Common Stock to Sr Vice President, Sales on 2026-08-05

Exercise price 0.0900 per share Conversion or exercise price for the options to buy Common Stock

Expiration date 2036-08-04 Options expire if unexercised by this date

Full vesting date 8/4/2030 Options become fully vested on this date under the vesting schedule

Post-transaction derivative holdings 250000.0000 options Total options to buy Common Stock held directly by the insider after the grant

Key Terms

Options to buy Common Stock, conversion or exercise price, vesting, Grant, award, or other acquisition

4 terms

Options to buy Common Stock financial

"security titled Options to buy Common Stock reported as a derivative award"

conversion or exercise price financial

"conversion or exercise price of 0.0900 per share for the options"

vesting financial

"options to vest 25% after one year, then monthly vesting until 8/4/2030"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Grant, award, or other acquisition financial

"transaction coded as Grant, award, or other acquisition of derivatives"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/07/2026 - 04:53 PM Accepted by SEC EDGAR 08/07/2026 - 04:52 PM

FAQ

What insider transaction did Zomedica Corp. (ZOMDF) report for Russell Kevin Klass?

Zomedica Corp. reported that Sr Vice President, Sales Russell Kevin Klass received a grant of 250,000 options to buy Common Stock on August 5, 2026, with an exercise price of 0.0900 per share and expiration on August 4, 2036, leaving him holding 250,000 options directly.

What are the key terms of the 250,000 options granted at Zomedica (ZOMDF)?

The award consists of 250,000 options to buy Zomedica Common Stock, with a conversion or exercise price of 0.0900 per share and an expiration date of August 4, 2036, all held directly by Sr Vice President, Sales Russell Kevin Klass after the grant.

How do the Zomedica (ZOMDF) options granted to Russell Kevin Klass vest?

According to the vesting schedule, one quarter (1/4) of the options vest on the first anniversary of the grant date, and the remaining three quarters vest in equal monthly installments (1/48 each month) until the grant is fully vested on August 4, 2030.

Is the Zomedica (ZOMDF) transaction a purchase or sale of shares?

The transaction is coded as a grant, award, or other acquisition of derivative securities, meaning options were awarded to Russell Kevin Klass. There is no reported sale or disposition of Zomedica Common Stock in this report, and his directly held options position became 250,000.

Was the Zomedica (ZOMDF) option grant made under a Rule 10b5-1 trading plan?

The Rule 10b5-1 checkbox for this Zomedica insider report is not checked, indicating the transaction is not affirmatively reported as being made under a Rule 10b5-1 trading plan. It is recorded simply as a grant or award of derivative securities to the executive.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klass Russell Kevin

(Last)

(First)

(Middle)

1101 TECHNOLOGY DRIVE

STE 100

(Street)

ANN ARBOR

MICHIGAN

48108

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zomedica Corp. [ ZOMDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Sr Vice President, Sales

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Options to buy Common Stock	$0.09	08/05/2026		A		250,000		⁽¹⁾	08/04/2036	Common Stock	250,000	$0	250,000	D

Explanation of Responses:

1. one quarter (1/4) of the options to vest on the first anniversary of the date of grant and 1/48 to vest monthly thereafter until fully vested on 8/4/2030

Remarks:

(1) one quarter (1/4) of the options to vest on the first anniversary of the date of grant and 1/48 to vest monthly thereafter until fully vested on 8/4/2030

	/s/ Kevin Klass	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR